StocksMedium•13 November 2026•
1 min read
Rezolute Prices $100M Public Offering to Fund Rare Disease Clinical Programs
Key Facts
1Rezolute announced the pricing of an underwritten offering of common stock and pre-funded warrants to raise approximately $100 million.
2The offering price was set at $3.87 per common share, with participation from new and existing investors led by Frazier Life Sciences.
Rezolute announced the pricing of an underwritten public offering of common stock and pre-funded warrants to raise approximately $100 million. GlobeNewswire reported that the offering price was set at $3.87 per common share, with participation from new and existing investors led by Frazier Life Sciences. The company intends to use the gross proceeds to fund its late-stage rare disease clinical programs and for general corporate purposes.
RZLT closed at $3.87 on November 12, 2026, matching the announced offering price. The stock traded between a low of $3.85 and a high of $4.13 on November 12, 2026, as the company secures capital to advance its treatments for refractory hypoglycemia caused by hyperinsulinism.